e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Lexaria Bioscience Corp.
< Previous
1
2
Next >
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
December 29, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Tickers
LEXX
LEXXW
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
November 10, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Death
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
November 03, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
November 01, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria's Technology Proven to Deliver Oral THC More Effectively
October 13, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Cannabis
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Oral Nicotine Study NIC-A21-1 Delivers Outstanding Results
October 05, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
September 08, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
September 07, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
July 28, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Supply Chain
Tickers
LEXX
LEXXW
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
July 27, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Receives US$3,817,643 From Warrant Exercises
July 26, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
July 22, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Death
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
July 21, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
July 15, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Receives Patent Protection in Japan
July 13, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
July 05, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Announces 2021 Annual Meeting Results
June 29, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 15, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Provides Progress Report on Six R&D Programs
June 09, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
June 07, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
June 03, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
May 20, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
May 12, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
May 07, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
May 06, 2021
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Tickers
LEXX
LEXXW
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.